Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus

The combination of lenvatinib, a multiple receptor tyrosine kinase inhibitor, plus everolimus, a mammalian target of rapamycin (mTOR) inhibitor, significantly improved clinical outcomes versus everolimus monotherapy in a phase II clinical study of metastatic renal cell carcinoma (RCC). We investigat...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cancer Sci
Main Authors: Matsuki, Masahiro, Adachi, Yusuke, Ozawa, Yoichi, Kimura, Takayuki, Hoshi, Taisuke, Okamoto, Kiyoshi, Tohyama, Osamu, Mitsuhashi, Kaoru, Yamaguchi, Atsumi, Matsui, Junji, Funahashi, Yasuhiro
格式: Artigo
語言:Inglês
出版: John Wiley and Sons Inc. 2017
主題:
Original Articles
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5406533/
https://ncbi.nlm.nih.gov/pubmed/28107584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13169
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍